NeuroSense Therapeutics reported that its ALS drug PrimeC achieved a statistically significant 65% reduction in the risk of death in a Phase 2b trial. Separately, the company was granted a South Korean patent covering PrimeC's composition, formulation, and use for ALS treatment through 2042.
The FDA granted Fast Track designation to COYA 302 for ALS. Phase 1 data showed tolerability and biomarker effects, and the phase 2 ALSTARS trial is underway.
New research reveals that ultra-marathon running damages red blood cells, making them less flexible and accelerating their breakdown. The study found this damage increases with race distance and could potentially lead to anemia. The findings may also help improve blood storage practices for medical transfusions.
Recent studies examine biological factors affecting sleep in older adults, finding connections between inflammatory markers, antioxidant capacity, and sleep quality in aging populations.
